Botswana vs Myanmar: Average cost of drugs for extensively drug-resistant tuberculosis
Botswana
900 constant 2022 US$
in 2024
Myanmar
963 constant 2022 US$
in 2024
Botswana rank
44th
Myanmar rank
43rd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Botswana
- Myanmar
How they compare
Myanmar currently reports 963 constant 2022 US$ against 900 constant 2022 US$ in Botswana, a difference of 63 constant 2022 US$.
That makes Myanmar's figure about 1.1 times Botswana's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Botswana ahead.
Botswana ranks 44th and Myanmar ranks 43rd of 56 countries.
Myanmar has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Botswana | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,178 constant 2022 US$ | 7,630 constant 2022 US$ | 452.67 constant 2022 US$ | Myanmar |
| 2020s | 1,200 constant 2022 US$ | 2,697 constant 2022 US$ | 1,497 constant 2022 US$ | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Botswana or Myanmar?
- Myanmar, at 963 constant 2022 US$ against 900 constant 2022 US$ in Botswana as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Botswana and Myanmar?
- 63 constant 2022 US$, with Myanmar ahead.
- How many years of comparable data are there for Botswana and Myanmar?
- 5 years are reported by both, from 2017 to 2024.
- How do Botswana and Myanmar rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Botswana ranks 44th and Myanmar ranks 43rd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.